Startup Spotlight: Glympse Bio hopes its test will show whether drugs are actually working

July 17, 2020

Cambridge, Mass.-based startup Glympse Bio has raised more than $45 million for its nanoparticle-based biosensors, and it’s hoping the alternative to traditional biopsies can help drug developers test whether their own medicines are actually treating a patient’s condition.


Access the full article on STAT Plus here: